CD8A and cancer: Additionally, some cancer-derived EVs express programmed death ligand 1 (PD-L1) on their surface, an inhibitory molecule that binds to its receptor (programmed-cell death protein 1 (PD-1)) and suppresses CD8+ cytotoxic T cell function (Chen et al., 2018).